George Bakris to Kidney Failure, Chronic
This is a "connection" page, showing publications George Bakris has written about Kidney Failure, Chronic.
Connection Strength
14.985
-
Slowing the Progression of Diabetic Kidney Disease. Cells. 2023 07 31; 12(15).
Score: 0.646
-
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 01; 103(1):196-206.
Score: 0.613
-
Intersection Between Chronic Kidney Disease and Cardiovascular Disease. Curr Cardiol Rep. 2021 07 16; 23(9):117.
Score: 0.561
-
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
Score: 0.498
-
Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. Am J Kidney Dis. 2016 Nov; 68(5S1):S15-S23.
Score: 0.405
-
Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. Am J Kidney Dis. 2016 Nov; 68(5S1):S5-S14.
Score: 0.405
-
Current and future potassium binders. Nephrol News Issues. 2016 Apr; 30(4):suppl 27-31.
Score: 0.389
-
Epidemiology of hypertensive kidney disease. Nat Rev Nephrol. 2011 Jan; 7(1):11-21.
Score: 0.268
-
Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010 Nov; 11(16):2675-86.
Score: 0.263
-
Overview of the KEEP international articles. Kidney Int Suppl. 2010 Mar; (116):S1.
Score: 0.255
-
Pediatrics: Masked hypertension: a risk factor in children with CKD. Nat Rev Nephrol. 2010 Mar; 6(3):132-4.
Score: 0.255
-
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010 Apr 03; 375(9721):1173-81.
Score: 0.254
-
Hypertension goals in advanced-stage kidney disease. Clin J Am Soc Nephrol. 2009 Dec; 4 Suppl 1:S92-4.
Score: 0.251
-
Glycemic control and cardiovascular disease in chronic kidney disease. Curr Diab Rep. 2009 Jun; 9(3):243-8.
Score: 0.242
-
The kidney, hypertension, and remaining challenges. Med Clin North Am. 2009 May; 93(3):697-715, Table of Contents.
Score: 0.241
-
Executive summary: Kidney Early Evaluation Program (KEEP) 2008 annual data report. Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S1-2.
Score: 0.239
-
Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S22-31.
Score: 0.239
-
Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S3-10.
Score: 0.239
-
The message for World Kidney Day 2009: hypertension and kidney disease--a marriage that should be prevented. J Hypertens. 2009 Mar; 27(3):666-9.
Score: 0.238
-
The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Blood Purif. 2009; 27(2):231-4.
Score: 0.238
-
Hypertension and kidney disease: a combination that should be prevented. Nephrol News Issues. 2009 Feb; 23(2):42, 44, 46.
Score: 0.237
-
Assessing blood pressure control in dialysis patients: finally a step forward. Hypertension. 2009 Mar; 53(3):448-9.
Score: 0.236
-
Renin-angiotensin blockade and kidney disease. Lancet. 2008 Aug 16; 372(9638):511-2.
Score: 0.229
-
CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Aug; 52(2):382-3.
Score: 0.229
-
Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008 Apr; 121(4):332-40.
Score: 0.223
-
Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. Postgrad Med. 2008 Apr; 120(1):33-42.
Score: 0.223
-
Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. J Nephrol. 2007 Nov-Dec; 20(6):703-15.
Score: 0.217
-
Should beta-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol. 2007 Sep; 27(5):555-64.
Score: 0.214
-
Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant. 2006 Sep; 21(9):2366-74.
Score: 0.197
-
Albuminuria and cardiovascular risk. Heart Fail Clin. 2006 Jan; 2(1):53-9.
Score: 0.191
-
Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr. 2006; 1(1):58-65.
Score: 0.191
-
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005 Apr 25; 165(8):947-53.
Score: 0.182
-
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004 Mar; 24(2):168-75.
Score: 0.168
-
Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004; 22(1):130-5.
Score: 0.166
-
Hypertension and nephropathy. Am J Med. 2003 Dec 08; 115 Suppl 8A:49S-54S.
Score: 0.166
-
Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients? Am J Kidney Dis. 2003 Dec; 42(6):1301-4.
Score: 0.165
-
Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet. Kidney360. 2023 11 01; 4(11):1650-1656.
Score: 0.164
-
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023 11; 25(11):3327-3336.
Score: 0.162
-
Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus. J Clin Hypertens (Greenwich). 2023 08; 25(8):737-747.
Score: 0.161
-
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Res Care. 2023 06; 11(3).
Score: 0.160
-
Hypertension in Patients Treated With In-Center Maintenance Hemodialysis: Current Evidence and Future Opportunities: A Scientific Statement From the American Heart Association. Hypertension. 2023 06; 80(6):e112-e122.
Score: 0.159
-
ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):420-3.
Score: 0.153
-
Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. J Card Fail. 2023 01; 29(1):87-107.
Score: 0.153
-
Hypertension and diabetes: family physicians' pivotal role. Am Fam Physician. 2002 Oct 01; 66(7):1151-2.
Score: 0.153
-
Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review. JAMA Cardiol. 2022 05 01; 7(5):549-555.
Score: 0.148
-
Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics. 2002; 20(1):37-47.
Score: 0.145
-
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021 07 13; 78(2):142-152.
Score: 0.139
-
Major adverse renal events (MARE): a proposal to unify renal endpoints. Nephrol Dial Transplant. 2021 02 20; 36(3):491-497.
Score: 0.136
-
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. Clin Pharmacol Ther. 2021 06; 109(6):1631-1638.
Score: 0.135
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
Score: 0.120
-
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
Score: 0.111
-
Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. Diabetes Care. 2018 03; 41(3):389-390.
Score: 0.111
-
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47.
Score: 0.110
-
Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801.
Score: 0.105
-
Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis. 2016 Nov; 68(5S1):S51-S58.
Score: 0.101
-
BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol. 2017 02; 28(2):671-677.
Score: 0.100
-
Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. J Am Soc Nephrol. 1995 Mar; 5(9):1684-8.
Score: 0.090
-
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med. 2015 Jul; 278(1):38-49.
Score: 0.089
-
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 12 26; 369(26):2492-503.
Score: 0.082
-
Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2013 Mar; 61(3):404-12.
Score: 0.077
-
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med. 2012 Jul; 125(7):661-9.
Score: 0.074
-
Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012 Jan 09; 172(1):41-7.
Score: 0.073
-
Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
Score: 0.072
-
Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis. 2011 Dec; 58(6):886-93.
Score: 0.071
-
Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73.
Score: 0.069
-
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S24-31.
Score: 0.068
-
Sustainable community-based CKD screening methods employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S4-8.
Score: 0.068
-
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2011 Mar; 57(3 Suppl 2):S9-16.
Score: 0.068
-
Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. Intern Med J. 2010 Dec; 40(12):833-41.
Score: 0.067
-
Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol. 2010 Dec; 21(12):2131-42.
Score: 0.066
-
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S23-33.
Score: 0.064
-
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010 Mar; 3(2):253-60.
Score: 0.063
-
The current state of RAAS blockade in the treatment of hypertension and proteinuria. Curr Cardiol Rep. 2009 Nov; 11(6):436-42.
Score: 0.062
-
Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich). 2009 Nov; 11(11):636-43.
Score: 0.062
-
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism. 2010 Mar; 59(3):385-9.
Score: 0.062
-
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis. 2009 Apr; 53(4 Suppl 4):S11-21.
Score: 0.060
-
World Kidney Day: hypertension and chronic kidney disease. Lancet. 2009 Apr 04; 373(9670):1157-8.
Score: 0.060
-
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008 Aug; 156(2):277-83.
Score: 0.057
-
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008 Apr 28; 168(8):832-9.
Score: 0.056
-
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007 Feb 01; 99(3):393-8.
Score: 0.051
-
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 Jan; 71(1):31-8.
Score: 0.051
-
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
Score: 0.050
-
An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol. 2006; 26(3):268-75.
Score: 0.049
-
Level of kidney function determines cardiovascular fate after coronary bypass graft surgery. Circulation. 2006 Feb 28; 113(8):1046-7.
Score: 0.048
-
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005 Feb; 19(2):139-44.
Score: 0.045
-
beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004 Dec 13-27; 164(22):2465-71.
Score: 0.044
-
Slowing the progression of diabetic nephropathy and its cardiovascular consequences. Am Heart J. 2004 Aug; 148(2):243-51.
Score: 0.043
-
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003 Jul 14; 163(13):1555-65.
Score: 0.040
-
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S154-65.
Score: 0.040
-
The rationale and design of the AASK cohort study. J Am Soc Nephrol. 2003 Jul; 14(7 Suppl 2):S166-72.
Score: 0.040
-
Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis. 2003 Jun; 41(6):1267-77.
Score: 0.040
-
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20; 288(19):2421-31.
Score: 0.038
-
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001 Jun 06; 285(21):2719-28.
Score: 0.035
-
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation. 2019 08 27; 140(9):739-750.
Score: 0.030
-
Microalbuminuria: prognostic implications. Curr Opin Nephrol Hypertens. 1996 May; 5(3):219-23.
Score: 0.024
-
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.
Score: 0.017
-
Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008 Feb; 51(2):192-8.
Score: 0.014